1.Hu H, Sawhney M, Shi L, Duan S. A systematic review of the direct economic burden of type 2 diabetes in China. Diabetes Ther. 2015;6(1):7–16. https://doi.org/10.1007/s13300-015-0096-0.
2.World Health Organization. Global report on dia- betes. Geneva: World Health Organization. https:// www.who.int/substance_abuse/publications/ global_alcohol_report/en/.. Accessed 8 Aug 2018.
3.Prendergast C, Gidding SS. Cardiovascular risk in children and adolescents with type 2 diabetes mellitus. Curr Diab Rep. 2014;14(2):454.
4.Bhupathiraju SN, Hu FB. Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. Circ Res. 2016;118(11):1723-1735.
5. Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol 2003;40 Suppl 1:S302-4
6.Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011;95(5):875-892.
7.Carroll C, Naylor E, Marsden P, et al. How do people with Type 2 diabetes perceive and respond to cardiovascular risk? [J]. Diabet Med. 2003, 20(5): 355-360.
8.Wang T, Xu Y, Xu M, et al. Awareness, treatment and control of cardiometabolic
disorders in Chinese adults with diabetes: a national representative population study [J]. Cardiovasc Diabetol. 2015, 14: 28.
9. Tabet, F, Remaley, A. T, Segaliny, A. I,. The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro[J]. Arteriosclerosis Thrombosis & Vascular Biology, 30(2):246-252.
10.Krimbou L, March M, Genest J. New insights into the biogenesis of human high-density lipoproteins. Curr Opin Lipidol, 2006, 17:258-267.
11.Tanigawa H, Billheimer JT, Tohyama J, et al. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol
transport.Circulation, 2007,116:1267-1273.
12.Vaisar T, Pennathur S, Green PS, et aL.Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest, 2001,117:746-756.
13.Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional
high-density lipoprotein. Curr Opin Lipidol, 2007, 18:427134.
14.Krause BR, Remaley AT.Reconstituted HDL for the acute treatment of
acute coronary syndrome[J]. Curr Opin Lipidol. 2013 Dec;24(6):480-6.
15.Yoshida M, Mita T, Yamamoto R, Shimizu T, Ikeda F, Ohmura C, et al. Combination of the Framingham risk score and carotid intima-media thickness improves the prediction of cardiovascular events in patients with type 2 diabetes. Diabetes Care 2012;35:178-80.
16. D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
17.Hafiane A(1), Kellett S,Genest J.Treatment options for low high-density
lipoproteins. Curr Opin Endocrinol Diabetes Obes[J]. 2014 Apr;21(2):134-9.
18].Joy TR(1). Novel HDL-based therapeutic agents[J]. Pharmacol Ther. 2012
Jul;135(1):18-30.
19.Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-50.
20.Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.
21.Krisela Steyn, Albertino Damasceno. Lifestyle and Related Risk Factors for Chronic Diseases[M]. PubMed, 2006.
22.Dhevaksha Naidoo, Adrian Schembri, Marc Cohen. The health impact of residential retreats: A systematic review[J]. Bmc Complementary & Alternative Medicine, 2018, 18(1).
23. E W Almqvist, R R Brinkman, S Wiggins,等. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease[J]. Clinical Genetics, 2003, 64(4):300-309.
24.Samuel D Gosling, Peter J Rentfrow, William B Swann. A Very Brief Measure of the Big-Five Personality Domains[J]. Journal of Research in Personality, 2003, 37(6):504-528.
25.Bacha F, Gungor N, Lee S, Arslanian SA. In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care. 2009;32(1):100-105.
26.Burns SF, Lee S, Bacha F, Tfayli H, Hannon TS, Arslanian SA. Pre-diabetes in overweight youth and early atherogenic risk. Metabolism. 2014;63(12):1528-1535.
27.Zhang XF, Attia J, D’Este K, Yu XH, Wu XG: Prevalence and magnitude of classical risk factors for coronary heart disease in a cohort of 4400 Chinese steelworkers over 13.5 years follow-up. Eur J Cardiovasc Prev Rehabil 2004, 11(2):113-120.
28.Simpson S H, Johnson J A, Biggs R S, et al. Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: a planned subgroup analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).[J]. 2012, 24(3):389-394.
29.Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y: Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring. Circulation 2001, 103(3):462-468.
30.Marialaura Bonaccio, Augusto Di Castelnuovo, Simona Costanzo, et al. Chili Pepper Consumption and Mortality in Italian Adults. J Am Coll Cardiol. 2019; 74(25). doi:10.1016/j.jacc.2019.09.068.31
31.Jun Lv, Lu Qi, Canqing Yu, et al. Consumption of spicy foods and total and cause specific mortality: population based cohort study. BMJ. 2015; 351: h3942.
32.Mustafa C , Benjamin L , Oreste G . The Association of Hot Red Chili Pepper Consumption and Mortality: A Large Population-Based Cohort Study[J]. PLOS ONE, 2017, 12(1):e0169876-.
33.Yang D , Luo Z , Ma S , et al. Activation of TRPV1 by Dietary Capsaicin Improves Endothelium-Dependent Vasorelaxation and Prevents Hypertension[J]. Cell Metabolism, 2010, 12(2):0-141.
34.Emons W H, Meijer R R, Denollet J. Negative affectivity and social inhibition in cardiovascular disease: evaluating type-D personality and its assessment using item response theory.[J]. 2007, 63(1):27-39.
35. Sturmer, T. Personality, lifestyle, and risk of cardiovascular disease and cancer: follow-up of population based cohort[J]. BMJ, 332(7554):1359-0.
36. Aysha Almas, Jette Moller, Romaina Iqbal. Effect of neuroticism on risk of cardiovascular disease in depressed persons-a Swedish population-based cohort study[J]. Bmc Cardiovascular Disorders, 2017, 17(1):185.